Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia.

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Abstract Text:

Tatsuya Suzuki,Kenzo Oba,Yoshimasa Igari,Noriaki Matsumura,Kentaro Watanabe,Shoko Futami-Suda,Hiroko Yasuoka,Motoshi Ouchi,Kazunari Suzuki,Yoshiaki Kigawa,Hiroshi Nakano,Tatsuya Suzuki,Kenzo Oba,Yoshimasa Igari,Noriaki Matsumura,Kentaro Watanabe,Shoko Futami-Suda,Hiroko Yasuoka,Motoshi Ouchi,Kazunari Suzuki,Yoshiaki Kigawa,Hiroshi Nakano,

BACKGROUND: Colestimide has been reported to lower blood glucose levels in patients with type 2 diabetes complicated by hypercholesterolemia. AIM: To examine the mechanism by which colestimide decreases plasma glucose levels in the above patients. METHODS: A total of 16 inpatients with type 2 diabetes complicated by hypercholesterolemia received colestimide for 1 week after their plasma glucose levels stabilized. We measured plasma glucose, serum immunoreactive insulin (IRI), serum lipid, plasma glucagon, and plasma glucagon-like peptide-1 (GLP-1) levels. These variables at baseline and 1 week of colestimide administration were compared. RESULTS: Preprandial plasma glucose levels (baseline: 132 +/- 33 mg/dL vs. completion: 118 +/- 43 mg/dL, P=0.073) tended to decrease after colestimide administration, while 1-hr postprandial plasma glucose levels (baseline: 208 +/- 49 mg/dL vs. completion: 166 +/- 30 mg/dL, P<0.001) and 2-hr postprandial plasma glucose levels (baseline: 209 +/- 56 mg/dL vs. completion: 178 +/- 39 mg/dL, P=0.015) decreased significantly at 1 week of colestimide administration. The 2-hr postprandial plasma GLP-1 level was significantly (P=0.015) higher at 1 week of colestimide administration as compared with the baseline level, while there were no significant changes in preprandial and 1-hr postprandial plasma GLP-1 levels. CONCLUSIONS: The GLP-1-increasing activity of colestimide may explain, at least in part, the mechanism of its blood glucose-lowering activity in patients with type 2 diabetes complicated by hypercholesterolemia.

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Publishing Authors By Initials

T Suzuki,K Oba,Y Igari,N Matsumura,K Watanabe,S Futami-Suda,H Yasuoka,M Ouchi,K Suzuki,Y Kigawa,H Nakano,T Suzuki,K Oba,Y Igari,N Matsumura,K Watanabe,S Futami-Suda,H Yasuoka,M Ouchi,K Suzuki,Y Kigawa,H Nakano,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of Nippon Medical School = Nihon Ika Daiga

VOLUME: 74

Page Numbers: 338-43

Journal Abbreviation:

ISSN: 1345-4676

DAY: 29

MONTH: Oct

YEAR: 2007

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100935589

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia.

AFFILIATION: Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. t.suzuki@nms.ac.jp

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Nippon Med Sch

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 7-36 levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia Related Publications

• 1.54-microm TM-mode waveguide optical isolator based on the nonreciprocal-loss phenomenon: device design to reduce insertion loss.
• A method for estimating 3-d nuclear parameters using an image taken from a hepatic histopathological section.
• Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
• Adolescent pregnancy: a comparative study between mothers who use public and private health systems.
• Antireflection microstructures fabricated upon fluorine-doped SiO(2) films.
• Association between promoter polymorphisms of nuclear factor-erythroid 2-related factor 2 gene and peptic ulcer diseases.
• Benomyl resistance of Colletotrichum acutatum is caused by enhanced expression of beta-tubulin 1 gene regulated by putative leucine zipper protein CaBEN1.
• Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia.
• Comparison of laser epithelial keratomileusis with and without mitomycin C for wavefront customized surface ablations.
• Constant blood flow reduction in premotor frontal lobe regions in ALS with dementia - a SPECT study with 3D-SSP.
• Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma.
• Dynamical study of femtosecond-laser-ablated liquid-aluminum nanoparticles using spatiotemporally resolved x-ray-absorption fine-structure spectroscopy.
• Efficient derivation of embryonic stem cells by inhibition of glycogen synthase kinase-3.
• Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and chronic gastritis.
• Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia.
• Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site.
• Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population.
• Native zona pellucida structure is required for completion of sperm acrosome reaction in porcine fertilization.
• Recombinant bovine zona pellucida glycoproteins ZP3 and ZP4 coexpressed in Sf9 cells form a sperm-binding active hetero-complex.
• Regulation of Respiratory Genes by ResD-ResE Signal Transduction System in Bacillus subtilis.
• Semivectorial H-field analysis of rib waveguides by a modified beam-propagation method based on the generalized Douglas scheme.
• Synthesis and aggregation behavior of meso-sulfinylporphyrins: evaluation of S-chirality effects on the self-organization to S-oxo-tethered cofacial porphyrin dimers.
• The new assessment of left atrial plication for giant left atrium.
• Toenail zinc level and gastric cancer risk in Cali, Colombia.
• Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer.
• Two-body Coulomb explosion and hydrogen migration in methanol induced by intense 7 and 21 fs laser pulses.
• [A case of primary lung cancer with cervical tuberculous lymphadenitis]
• [Brain perfusion imaging in amyotrophic lateral sclerosis with dementia]
• [Drug-induced aseptic meningitis]
• [Thrombosis--adverse effect of drugs]